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Abstract
Background: The effect of maraviroc on the maintenance and the function of HIV-1-specific T cell responses remains
unknown.
Methods: Subjects recently infected with HIV-1 were randomized to receive anti-retroviral treatment with or without
maraviroc intensification for 48 weeks, and were monitored up to week 60. PBMC and in vitro-expanded T cells were tested
for responses to the entire HIV proteome by ELISpot analyses. Intracellular cytokine staining assays were conducted to
monitor the (poly)-functionality of HIV-1-specific T cells. Analyses were performed at baseline and week 24 after treatment
start, and at week 60 (3 months after maraviroc discontinuation).
Results: Maraviroc intensification was associated with a slower decay of virus-specific T cell responses over time compared
to the non-intensified regimen in both direct ex-vivo as well as in in-vitro expanded cells. The effector function profiles of
virus-specific CD8+ T cells were indistinguishable between the two arms and did not change over time between the groups.
Conclusions: Maraviroc did not negatively impact any of the measured parameters, but was rather associated with a
prolonged maintenance of HIV-1-specific T cell responses. Maraviroc, in addition to its original effect as viral entry inhibitor,
may provide an additional benefit on the maintenance of virus-specific T cells which may be especially important for future
viral eradication strategies.
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Introduction
Maraviroc is an antiretroviral agent that blocks HIV-1 entry by
binding the virus’ coreceptor CCR5. Given its molecular target,
maraviroc treatment may modulate the natural expression and
function of CCR5, and negatively affect chemotaxis and effector
function of Th1-type CD4+ T cell and memory CD8+ T cells.
Maraviroc may have additional immunomodulatory effects by
blocking the binding of the natural ligands of CCR5 (MIP-1a,
MIP-1b and, RANTES), yet little data exist on how maraviroc
may interfere with the cellular host immunity, especially the one
directed against HIV-1.
While CCR5 deficiency (in the form of a 32 base-pair
homozygous deletion) can mediate resistance to HIV-1 infection
[1–3], it also has the potential to impair control of other viral
infections, such as West Nile virus (WNV), both in mouse and
humans [4,5]. In particular, murine T cells lacking CCR5
expression have been shown to secrete lower amounts of IL-2
compared to CCR5+ T cells, and a similar phenotype has been
observed in T cells from humans expressing the CCR5-:32
mutation [6]. Furthermore, CD8+ T cell exhaustion during
chronic Lymphocytic choriomeningitis virus (LCMV) infection is
more severe in the absence of RANTES, one of the natural CCR5
ligands [7]. Thus, although CCR5-:32 homozygosity does not
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seem to negatively affect humans, blocking its function by agents
like maraviroc may negatively affect immune responses, including
T cell responses to HIV-1.
In previous clinical trials, treatment with maraviroc has been
shown to result in more extensive increases in CD4 counts in
treatment-naı¨ve and -experienced subjects, though the mecha-
nisms involved remain unknown [8–11]. In addition, some studies
have indicated that adding maraviroc to suppressive combination
antiretroviral treatment (cART) reduces markers of immune
activation [12–15]. Also, in vitro exposure to maraviroc decreases
some markers of immune activation on T lymphocytes [16]. While
these findings suggest that maraviroc may have beneficial effects
on global host immune status, maraviroc has also been found to
increase T cell activation both in gut and peripheral blood [17].
Thus, it is still controversial whether maraviroc has net
immunological benefits or disadvantages on host cellular immune
responses. In addition, the impact of maraviroc on antigen-specific
T cell responses, especially towards HIV-1-derived antigens, has
not been assessed, despite its potential implications with regards to
immune interventions, particularly therapeutic vaccination in
maraviroc treated subjects. To address these issues, we analyzed in
a longitudinal study the effects of cART versus maraviroc–
intensified cART on the maintenance (breadth, magnitude and
specificity) of HIV-1-specific T cell responses, their differentiation
potential and their polyfunctionality.
Materials and Methods
Study design
The present study was performed as sub-study of the
Maraviboost study (ClinicalTrials.gov Identifier: NCT00808002).
The Maraviboost study was a multi-center, randomized, open-
label, phase III clinical trial. The main goal of the parental clinical
trial was to assess whether intensification with maraviroc in
recently HIV-1 infected patients with standard triple therapy
could accelerate the decay of the HIV-1 reservoir [18]. Thirty
subjects recently infected with CCR5-tropic HIV-1 (subtype B)
were recruited and randomized into 2 groups (n = 15 each), one
being treated with triple therapy consisting of Raltegravir (RAL)
plus Tenofovir (TDF)/Emtricitabine (FTC) alone while the second
group received additionally maraviroc (MVC) intensification for
the first 48 weeks in the trial. The primary end point of the main
study was week 48, but patients were followed until week 72 if
possible. Frozen PBMC from pre-defined time points before
starting cART (baseline, BL), 24 weeks after study initiation, and
12 weeks after maraviroc discontinuation (week 60), were analyzed
in the present study. One patient without maraviroc intensifica-
tion, who dropped out the study because of adherence problem,
was excluded from the analysis. Three patients (01028, 01039,
23012) were lost at week 24 (n = 1) or 36 (n = 2), respectively. All
patients received RAL plus TDF/FTC after week 48 except 4
patients (01021, 01031, 01034, 01043), who changed their anti-
HIV drug regimen. Of the 29 individuals, peripheral blood
mononuclear cells (PBMC) from at least one time point were
available for 13 patients with maraviroc intensification (MVC arm)
and 14 patients without MVC intensification (Control, CNT arm,
Table 1). The study was approved by the ethics committee of
Hospital Germans Trias i Pujol, Badalona, Spain. All patients gave
their written informed consent before enrolling in the study.
Flow cytometry for T cell phenotype analysis
PBMC were thawed and rested overnight at 37uC in
RPMI1640 supplemented with 10% heat-inactivated FCS,
100 U/ml penicillin, 100mg/ml streptomycin, and 2 mM gluta-
mine (R10). The following day, the cells were stained with LIVE/
DEAD Fixable Dead Cell Stain Kits (Invitrogen), washed and
stained with the following antibodies: anti-CD3-APC-Cy7, anti-
CD4-V450, anti-CD8-PE-Cy7, anti-CD45RA-APC (BD
Biosience), and anti-CCR7-PE (e-BioScience). The cells were
washed and fixed with 1% Formaldehyde in PBS. All data were
collected on a BD LSR II flow cytometer (BD Biosience) and
analyzed using FlowJo 8.7.7 (TreeStar).
Peptides
A set of 410 overlapping-peptides (OLPs) was used to screen for
HIV-specific T-cell responses [19]. The peptides spanned all HIV-
1 proteins and were based on the HIV clade B consensus sequence
of 2001, available at the Los Alamos National Laboratory HIV
immunology database. For ELISpot analyses, peptides were used
in a matrix layout of 6–12 peptides per pool for comprehensive
screening as previously described [19]. Reconfirmations of all
positive wells in the matrix screen were performed the following
day on a single-peptide base. For multi-functional analysis by flow
cytometry, peptide pools were used that contained peptides
spanning either full-length Gag, Protease, RT, IN, gp120, gp41,
or Nef. Peptides spanning Tat, Rev, Vif, Vpr, and Vpu were
combined into one peptide pool (accessory proteins peptide pool.
‘‘Acc’’).
IFN-c ELISpot assay using ex-vivo PBMC and in-vitro
expanded T cells
Thawed PBMC were rested for 3 hrs at 37uC in R10. If
sufficient PBMC were recovered, thawed cells were used directly
in IFN-c ELISpot assays (11 and 7 samples at baseline, 6 and 7
samples at week 24, and 8 and 7 samples at week 60 in the CNT
and MVC arm, respectively). In addition, 16106 thawed cells were
stimulated with an anti-CD3 monoclonal antibody and cultured
for 2–4 weeks in R10 supplemented with 50 U/ml of recombinant
IL-2 [20]. Before use in ELISpot assays, the expanded cells were
washed twice with R10 and incubated overnight at 37uC in the
absence of IL-2. Per well, 75,000–100,000 cells were used and
peptides were added as in the direct ex-vivo assay. Thresholds for
positive responses were defined as 1) at least five spots (50–66
SFC/106 PBMC) per well, 2) as responses exceeding the mean of
negative wells plus 3 standard deviation and 3) responses
exceeding three times the mean of negative (no peptide) wells;
whichever was the highest. For reconfirmation ELISpot, the
remaining cells and cells from negative wells from initial matrix
screens were recycled as previously described [20].
Flow cytometric analysis of CD8+ T cell function
Thawed PBMC were rested overnight at 37uC in R10. The
following day, costimulatory antibodies (anti-CD28 and anti-
CD49d at 1mg/ml; BD Biosciences) and monensin (GolgiStop; BD
Bioscience) were added, and cells were stimulated with the
different peptide pools (5mg/ml per peptide) as indicated. A
negative (no peptide) and a positive control (phorbol-12-myristate-
13-acetate (PMA at 10 ng/ml and ionomycin, 1mM) were included
in each assay. Following incubation for 6 hrs, the cells were
washed with PBS containing 1% FCS and the fluorescent reactive
dye (Invitrogen) for dead cells was added. Cells were washed again,
and stained with anti-CD3-V450, anti-CD8-PerCP, and anti-
CD107a-PE (BD BioScience). Following washing, the cells were
fixed and permeabilized using Fix & Perm cell permeabilization
reagents (Invitrogen). The cells were then stained with anti-MIP-
1b-FITC, anti-IL-2-PE-Cy7, anti-IFN-c-APC (BD Bioscience).
Data were collected on a BD LSR II flow cytometer (BD
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Biosience) and analyzed using FlowJo 8.7.7 (TreeStar). After
gating for each effector function, a Boolean gate platform was used
to create the full array of possible combinations and SPICE
software (version 5.22) was used to analyze the polychromatic flow
cytometry data. We applied a threshold for positive responses
using negative values distribution after background subtraction
(i.e. unstimulated cultures), as previously described [21].
Statistical analyses
Statistical analyses were performed using Graph Pad Prism 5.0.
The results are given as medians and interquartile range (IQR) as
indicated. Mann-Whitney test and Wilcoxon matched paired test
were used for unpaired and paired comparisons, respectively. For
multiple comparison analysis, we performed Bonferroni correc-
tion. Correlations between ex-vivo and in-vitro ELISpot data were
analyzed by using Spearman’s rank correlation coefficient, and
linear regression analysis.
Results
Changes in CD4+ and CD8+ T cell count and their
differentiation status
HIV-1-specific T cell responses are known to decrease upon
cART initiation, although not all responses and specificities may
show similar decay kinetics [22,23]. To determine whether
maraviroc-intensified cART would lead to an equally rapid or
even faster decay of global T cell responses to HIV-1, longitudinal
changes in the breadth and magnitude of total HIV-1-specific T
cell responses were compared between the maraviroc and control
study arms at week 24 and week 60, i.e. 12 weeks after stopping
maraviroc intensification. As previously reported, plasma viral
load decreased under the limits of detection within the first 4-week
cART in most patients [18]. CD4+ T cell counts showed higher
increases in the MVC subjects at week 12 and were significantly
elevated in the MVC arm at week 60 when compared to the
control subjects (p = 0.0378, Table 1 and ref [18]). At the same
time, the decay in CD8+ T cells was significantly slower in MVC
subjects than in the control subjects (Fig. 1A and [18]) To examine
whether these effects on CD4+ and CD8+ T cell counts were
associated with a modulation of T cell differentiation markers, the
expression of CD45RA and CCR7 was assessed over time and
compared between the two groups. The data show that the
frequency of effector memory (EM, CD45RA2/CCR72) CD8+ T
cells was significantly decreased in both study arms at week 24 and
week 60 compared to baseline, possibly reflecting the strong
reduction in viral loads in both arms upon cART initiation
(Fig. 1B). No significant changes for any other CD4+ or CD8+ T
cell subset was observed, neither over time nor between study
arms. These data indicate that maraviroc does not affect T cell
differentiation during and after maraviroc intensification and that
the different kinetics of CD4+ and CD8+ T cell counts between the
arms are not reflected by gross alterations in differentiation
markers.
Maraviroc intensification is associated with maintenance
of HIV-1-specific T cell responses
To assess whether the effect of maraviroc intensification on cell
homeostasis affected the magnitude, breadth and specificity of the
HIV-1-specific T cell response, we performed IFN-c ELISPOT
assay on PBMC from individuals in both arms of the study using a
18-mer overlapping peptide (OLP) set covering the full HIV-1
proteome [19]. At baseline, the median magnitude of HIV-1-
specific T cell responses in all patients was 2,708 SFC/106 PBMC
(range 395–13,860), with a median breadth of 6 (range 2–15)
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responses per individual (Fig 2, left hand panels). The magnitude
and the breadth in this cohort were considerably lower than that of
chronically infected patients reported previously but in line with
described breadth of responses in early, untreated HIV-1 infection
[19,24]. No significant difference was observed in magnitude and
breadth of HIV-1-specific response between the arms at any time
point (Fig. 2, right panels). When we assessed changes in the virus-
specific response in each arm, the magnitude of the HIV-1-specific
response in the control arm was significantly reduced by week 24
(median 454 SFC/106 PBMC (range 27–7584), p = 0.0042) and
even more so by week 60 (median 115 SFC/106 PBMC (range 0–
1,475), p = 0.0043, Fig 2A). In contrast, subjects in the MVC arm
did not show a significant reduction until week 60 when their
median magnitude was still more than 5-fold higher than
responses in the control arm (median 691 SFC/106 PBMC (range
0–3,535), Fig 2A). Similarly, the breadth of response was reduced
over time as well, with significant reductions seen by week 60 in
the control arm but not in the maraviroc intensified group (Fig 2B).
There was no difference between the arms in regards to protein
specificity of the HIV-1-specific CD8+ T cells that remained at 24
and 60 weeks after starting cART (data not shown).
To extend the longitudinal analyses of responses between the
intensified and non-intensified arms of the study to additional
individuals for whom sample availability was limiting, we
performed the same analysis using in vitro expanded cells. Aside
from including additional individuals into the analyses, this also
offered the opportunity to test for potential differences in the
proliferative capacities of HIV specific T cells in the two arms.
Thawed PBMC were expanded using an anti-CD3 mAb and kept
in culture until sufficient cell numbers were reached. The culture
time needed between the two study arms was comparable (both
arms a median of 19 days), indicating intact proliferative capacities
of T cells in maraviroc intensified cART treated individuals. For
samples for which direct ex-vivo PBMC and in vitro expanded cells
were tested, the ELISpot results were compared to validate the
approach of using in vitro, unspecifically expanded cells. Overall,
the breadth of responses in expanded cells correlated well with the
direct ex-vivo results (Fig 3A, r = 0.78, p,0.0001). The magnitude
of responses was generally increased in expanded cells, with later
time points (week 24 and 60) showing stronger recovery of
responses when compared to unexpanded cells (Fig. 3B). Of note,
the correlation between results from direct ex-vivo analyses and in-
vitro stimulated cells became stronger over time (r = 0.5235,
0.8455, 0.8720, and p = 0.0374, 0.0018, 0.0004 for comparisons
at BL, w24, and w60 respectively). No differences were observed in
proliferative capacity between the arms These data indicate that in
both arms, HIV-1-specific T cell responses showed intact in-vitro
proliferative capacities after prolonged cART and that in settings
with limited sample availability, the in-vitro expansion approach
produces reliable data [25].
HIV-1-specific T cell responses measured in expanded cells
showed a significant decline in their magnitude during first 24
weeks in all subjects together (Fig. 3C, left panel). However, the
reduction was generally less than three-fold (median 8,110 SFC/
106 PBMC in BL and 2,656 SFC/106 PBMC in week 24) and thus
not as dramatic as in unexpanded cells (median 6.3 fold,
2,708 SFC/106 PBMC in BL, and 424 SFC/106 PBMC in w24)
(Fig. 2A and 3C, left panel). When the longitudinal changes in
magnitude and breadth of responses were analyzed for each
treatment arm separately, no significant reductions at week 24 and
week 60 were noted (Fig 3C, D). However, when in-vitro stimulated
responses were compared between the two arms, there was a trend
that MVC-intensified subjects maintained stronger HIV-1-specific
response at week 24 than control individuals (median 1,450 (IQR
277–2,965) in the control arm, 3,957 (1,714–13,018) in MVC,
p = 0.0625, Fig. 3C, right panel). In addition, the median HIV-
specific response was three-fold higher in MVC (median 3,957
(275–4,691)) compared to the control arm (1,114 (2,394–6,882))
until week 60. These data further support the notion that HIV-1-
specific T cell responses are maintained for longer at higher levels
in subjects with maraviroc intensification compared to individuals
receiving non-intensified cART.
Poly-functionality of HIV-1-specific CD8+ T cells is
maintained under MVC intensified cART
The ability of HIV-1-specific T-cells to respond to antigenic
stimulus with multiple different effector functions has been
associated with the relative control of HIV-1 infection [26,27].
Since therapeutic strategies that aim at prolonged treatment
interruptions or even viral eradication, will possibly depend on
such polyfunctional T cell responses, we assessed the effector
functions of HIV-1-specific CD8+ T cells in cART treated subjects
with and without maraviroc intensification. To this end, direct ex-
vivo isolated PBMC were stimulated using peptide pools covering
each of the viral proteins and analyzed for the expression of the
degranulation marker (CD107a) or the production of intracellular
cytokines, including IFN-c, MIP-1b, and IL-2. The frequency of
IFN-c producing T cell responses correlated well with the data
from the ex-vivo ELISpot analyses (Fig 4A, r = 0.8265, p,0.0001).
The magnitude of the total HIV-1-specific CD8+ T cell responses
with at least one effector function by flow analysis varied widely in
baseline samples (0.43% to 16.44% of total CD8+ T cells across
arms) and, as expected, was reduced at week 24 and week 60
(Fig. 4B). Although the magnitude of total HIV-specific CD8+ T
cells between the arms was comparable at the different time points,
a significant reduction in the strength of the ex-vivo response was
seen in the control arm but not in MVC arm, as observed in direct
ex vivo ELISpot analysis (Fig. 1A and 4B). Also, as the reduction in
frequency of HIV-specific CD8+ T cell fractions with different
cytokine secretion pattern was similar between the two arms, the
data indicate that maraviroc intensification does not skew HIV-
specific CD8+ T cell function (Fig. 4C). The same was observed
when the relative contribution of T cell populations with different
numbers of effecter functions to the total HIV-specific CD8 T cell
responses was compared between arms and over time (Fig. 4D),in
line with previous reports [26,28].
Discussion
Since its development as a HIV entry inhibitor, CCR5 has been
used as a target in several clinical studies of HIV infection as well
as in other applications, including auto-immune diseases, cancer
and transplantation [15,29–34]. Although some results remain still
controversial [11–15,17,32] blocking the CCR5 co-receptor is
Figure 1. Differentiation status in CD4+ and CD8+ T cells. A. Changes of CD4+ and CD8+ T cell count in each subject. B. The proportion of naı¨ve
(CD45RA+/CCR7+), central memory (CM, CD45RA2/CCR7+), effector memory (EM, CD45RA2/CCR72), and Terminal effector memory (TEMRA, CD45RA
+/
CCR72) cells among CD4+ and CD8+ T cells in the control (cross and hatched line) and MVC arm (circle and solid line). The median and interquartile
range (vertical line) are shown. Stars (control) and hatches (MVC arm) above the lines indicate significant differences relative to baseline values (p,
0.05).
doi:10.1371/journal.pone.0087334.g001
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thought to suppress adverse immune activation and inflammation
by blocking the chemotactic activity via its inhibition of CCR5-
mediated signals. Due to its potential immune-modulatory
properties, maraviroc may thus also affect the HIV-specific
immune response, not necessarily only in a beneficial manner.
While a number of studies have described effects on total T cell
counts, CD4+ and CD8+ T cell kinetics and outcome of
vaccination to other pathogens [35–39], no study has, to our
knowledge, investigated the effect of MVC on the total HIV-1-
specific CD4+ and CD8+ T cell response. In the present study, we
investigated the effect of maraviroc intensification on HIV-specific
T cell responses in primary HIV-1 infected subjects treated with
standard cART or maraviroc intensified regimen. Although there
was no gross difference in specific T cell subsets, maraviroc
intensification showed extended maintenance of stronger HIV-1-
specific T cell responses when compared to non-intensified
treatment in PBMCs.
Our data in recently infected and early treated individuals
showed that maraviroc intensification accelerated recovery of
CD4+ T cell counts and maintained higher CD4+ T cell count
after its discontinuation (Table 1 and [18]). As CD4+ T cell help is
critical for maintenance of memory CD8+ T cells [40], this early
increase of CD4+ T cells may also provide the basis for the
extended maintenance of virus-specific T cell responses. Alterna-
tively, the maintenance of higher HIV-1-specific T cell responses
in maraviroc intensified subjects may be a reflection of a slower
reduction in the total CD8+ T cells in the peripheral blood. This
would be in line with clinical data showing that maraviroc
intensification increase CD4+ T cells faster and reduce CD8+ T
cell slower than non-intensified regimen (Fig. 1A and [18]). In
addition, others have recently reported that maraviroc intensifi-
cation increased CD8+ T cell counts in peripheral blood and
decreased CD8+ T cells in rectal tissue in chronically HIV-infected
subjects on stable cART [17], suggesting a possible in vivo
redistribution of T cells by maraviroc. However, the relative
changes of total CD8+ T cell counts between control arm and
intensified group were less pronounced than the extensive changes
in HIV-specific CD8+ T cell frequencies, making it unlikely that a
MVC-driven redistribution of virus-specific CD8+ T cells would be
the sole driving force behind the prolonged maintenance of these
cells in the peripheral blood. Maintenance of virus-specific T cells
has also be linked to the availability of cognate antigen[22]. As the
reduction in virmeia in both arms was comparable, additional
mechanisms may be at work in maraviroc-intensified individuals
that lead to extended presence of cells. As shown in previous
analyses, not all HIV-specific T cell response contract with the
same kinetics and some even expand after cART initiation[23]. As
there were no differences in the specificity of HIV-specific T cell
response between the two arms in the present study, the
mechanism for the maintenance of responses in the MVC
intensified group remain unclear. One possibility is that the slower
CD4 T cell decline in the intensified arm [18], together with a
Figure 2. Longitudinal analyses of HIV-1-specific T cell responses in PBMC. The total magnitude (A) and breadth (B) of ELISpot responses at
baseline (BL), week 24 (w24) and week 60 (w60) are shown for all subjects together (left panels) and for each study arm separately (right panels,
crossed lines for control arm, circles for MVC arm). Horizontal lines represent median values of Spot-forming cells (SFC)/106 PBMC and the IQR,
respectively. Mann-Whitney test was used in all statistical analysis. Only p values with significance after Bonferroni correction was shown. The
numbers in parenthesis below the x-axis represent the median value.
doi:10.1371/journal.pone.0087334.g002
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Figure 3. Longitudinal assessment of HIV-specific T cell responses with in vitro expanded T cells. A. Relationship of the breadth between
responses detected by direct ELISpot and ELISpot using in vitro expanded cells. Responses on the x-axes represent the total HIV-1-specific responses
in direct ELISpot, and the y-axes indicate total HIV-1-specific responses in expanded ELISpot for samples taken at baseline (circle), week 24 (square),
and week 60 (triangle). B. Relationship of the magnitude between direct ELISpot and expanded ELISpot at each time point. cross: control arm, circle:
MVC arm. The lines in A and B show linear regression lines. C, D. Changes in magnitude and breadth of total HIV-specific T cell responses in expanded
ELISpot are shown as in Figure 2.
doi:10.1371/journal.pone.0087334.g003
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reported increased in T cell activation upon maraviroc intensifi-
cation [17] maintains activated CD8 T cell for longer. Although a
number of studies show conflicting data in terms of immune
activation [11–15], it is important to note that the present data
were generated in early treated subjects, which may yield different
results than the analyses in maraviroc intensification during
chronic HIV infection.
Blocking CCR5 signaling in-vivo might inhibit migration of
memory T cells expressing CCR5 to the site of the cognate
antigen, thus preventing these memory T cells to be stimulated
properly to acquire effector functions and exert effective anti-viral
immunity. In fact, maraviroc has been shown to inhibit
chemotactic activity of lymphocytes and monocytes in vitro and
to reduce the risk of Graft-versus-host disease (GVHD) in patients
Figure 4. Longitudinal assessment in functional profile of HIV-specific CD8+ T cells during cART with MVC intensification. A.
Correlation between the total HIV-specific responses determined by direct ex-vivo ELISpot analysis (as spot-forming cells (SFC)/106 PBMC) and by ICS
analysis (% of IFN-c+ CD8+ T cells). Linear regression line, and correlation coefficient and p-values (Spearman’s rank correlation test) are shown. B. The
change in total HIV-specific CD8+ T cell frequency over time by ICS analysis. Horizontal lines indicate median values of all positive responses. P values
were determined by Mann-Whitney tests and shown if the significance remains after Bonferroni correction. C, D. Effector function profiles of HIV-
specific CD8+ T cells over time in controls and MVC treated subjects. (left, baseline; middle, week 24; right, week 60). The median and IQR are
indicated by horizontal lines and boxes, respectively. Differences relative to baseline values in each arm were tested for statistic significance by Mann-
Whitney tests, and shown as # for p,0.05, ## for p,0.01.
doi:10.1371/journal.pone.0087334.g004
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with hematologic cancers after allogeneic hematopoietic stem cell
transplantation [16,30,41]. CCR5 polymorphisms and gene copy
number of CCL3L, encoding one of CCR5’s ligands, can affect
delayed-type hypersensitivity (DTH) response [42], suggesting that
CCR5 is critical for differentiation of CD8+ T cell, the acquisition
of effector functions and the ability to traffic to the site of viral
replication. However, we didn’t observe any difference in T cell
differentiation between the arms, and our data using directly
isolated PBMC and in vitro expanded T cells indicate that the
proliferative capacity of HIV-1-specific CD8+ T cells in Maraviroc
intensified subjects were not compromised. Furthermore, the
effector function profiles were essentially identical between the two
treatment arms, suggesting that maraviroc intensification does not
negatively affect the quality of HIV-1-specific CD8+ T cells. This is
further supported by studies of the effects of maraviroc intensifi-
cation on response to vaccination and immune profile in HIV-1
infected subjects [35]. Thus, studies of T cell effector function
profiles in maraviroc intensified therapy, including their ability to
mount HIV epitope-specific DTH reactions [43] may offer
interesting insights into how maraviroc can modulate, and
potentially improve, anti-viral immunity. In light of recent studies
showing reduced viral reservoir sizes in MVC treated individuals
[15] and data suggesting that a robust and functional HIV-1-
specific CD8+ T cell responses may be required for viral
eradication strategies [44], a prolonged maintenance of function-
ally intact virus-specific T cells could provide the patient with a
crucial advantage to further reduce the viral reservoir.
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